核心结合因子急性髓性白血病的核心概念:目前对预后和治疗的考虑
Christina Darwish1, Kyle Farina2, Douglas Tremblay1
1Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA.
Blood reviews
|July 31, 2023
概括
核心结合因子急性髓性白血病 (CBF AML) 的缓解率很高,但复发风险也很高. 优化治疗和利用可测量的残留疾病检测是改善CBFAML患者生存结果的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 核心结合因子急性髓性白血病 (CBF AML),其特征是t(8;21) 或 inv(16) 染色体异常,是急性髓性白血病的一个独特的亚型.
- 虽然CBFAML通常具有良好的预后和高的完全缓解率,但诱导化学疗法后的复发风险仍然很高,这仍然是一个重大挑战.
- 改善无复发存活率和复发后存活率需要优化治疗策略和更深入地了解疾病生物学.
研究的目的:
- 审查CBFAML目前的治疗环境,从初始诊断到复发.
- 突出新兴的研究和积极的调查领域,旨在改善CBFAML患者的治疗结果.
- 讨论新药和监测技术在优化治疗计划中的作用.
主要方法:
- 对当前治疗方法和CBFAML正在进行的研究的文献综述.
- 对评估gemtuzumab,高剂量cytarabine,低甲基化剂和激酶抑制剂的最近研究的分析.
- 讨论可测量的残留疾病 (MRD) 测试在疾病监测和治疗决策中的有用性.
主要成果:
- 目前的研究重点是优化诱导和巩固化疗,探索新的向疗法,并定义全源干细胞移植的作用.
- 可测量的残留疾病检测正在成为监测缓解和识别可能受益于强化治疗或移植的患者的关键工具.
- 包括新药和干细胞移植在内的各种治疗方式的最佳时间和整合正在积极调查中.
结论:
- 尽管最初的反应是有利的,但复发仍然是CBFAML的一个重大问题,这强调了需要先进的治疗策略的需要.
- 个性化治疗计划,包括新药和通过MRD测试进行精确监测,对于提高CBF AML的长期结果至关重要.
- 对复发的早期检测和有效的救援疗法的持续研究对于改善这种患者群体的存活率至关重要.
相关概念视频
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:22Bone Marrow Sampling and Transplants
360
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
01:01Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
01:28Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K